Key result
Trimetazidine may improve myocardial perfusion and LV function in ischemic cardiac dysfunction.
Why the study?
Trimetazidine's potential to improve myocardial uptake of Tc-99m tetrofosmin and left ventricular function in ischemic cardiac dysfunction was not fully established.
Does oral trimetazidine improve myocardial perfusion and left ventricular function in patients with ischemic left ventricular dysfunction?
Does oral trimetazidine improve myocardial perfusion and left ventricular function in patients with ischemic left ventricular dysfunction?
Trimetazidine may improve myocardial perfusion and left ventricular function in ischemic cardiac dysfunction, potentially aiding in the detection of hibernating myocardium on SPECT imaging.
Does not support routine use in ischemic dysfunction; leaves open whether trimetazidine aids viability assessment in prospective trials.
Trimetazidine (TMZ) has an antiischemic effect unrelated to changes in myocardial oxygen supply-to-demand ratio. TMZ improves energy metabolism during ischemia and protects myocardial cells against ischemic damage to mitochondrial function. The preserved mitochondrial metabolism might explain the increased cardiac uptake of Tc-99m tetrofosmin or Tc-99m sestamibi on myocardial SPECT in patients with coronary artery disease. Oral administration of TMZ might improve myocardial uptake of Tc-99m tetrofosmin and left ventricular function in ischemic cardiac dysfunction. Treatment with TMZ before myocardial Tc-99m tetrofosmin SPECT could help in revealing hibernating myocardium.
No takes yet. Share an insight, caveat, or question.
Feola et al. (2004) conducted a review in Ischemic Left Ventricular Dysfunction. Trimetazidine was evaluated. Oral administration of trimetazidine may improve myocardial perfusion and left ventricular function in ischemic cardiac dysfunction, potentially helping to reveal hibernating myocardium.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: